[A18-44] Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V

Last updated 01.10.2018

Project no.:

Commission awarded on 29.06.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adults with advanced (unresectable or metastatic) melanoma

Result of dossier assessment:

Treatment-naive patients with BRAF V600 mutant tumour and pretreated patients: added benefit not proven. Treatment-naive patients with BRAF V600 WT tumour: indication of lesser benefit


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2018-12-20 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form